PRIVA-CANDESARTAN TABLET

Страна: Канада

Язык: английский

Источник: Health Canada

Активный ингредиент:

CANDESARTAN CILEXETIL

Доступна с:

PHARMAPAR INC

код АТС:

C09CA06

ИНН (Международная Имя):

CANDESARTAN

дозировка:

32MG

Фармацевтическая форма:

TABLET

состав:

CANDESARTAN CILEXETIL 32MG

Администрация маршрут:

ORAL

Штук в упаковке:

100

Тип рецепта:

Prescription

Терапевтические области:

ANGIOTENSIN II RECEPTOR ANTAGONISTS

Обзор продуктов:

Active ingredient group (AIG) number: 0135220004; AHFS:

Статус Авторизация:

CANCELLED PRE MARKET

Дата Авторизация:

2018-03-06

Характеристики продукта

_Priva-CANDESARTAN _
_ _
_ _
_ _
_ _
_ _
_ _
_ _
_ _
_ _
_Page 1 of 35 _
_ _
PRODUCT MONOGRAPH
PR
PRIVA-CANDESARTAN
Candesartan Cilexetil Tablets
4 mg, 8 mg, 16 mg and 32 mg
Angiotensin II AT
1
Receptor Blocker
PHARMAPAR INC.
DATE OF PREPARATION:
5950, Côte de Liesse, Suite 100
June 15, 2016
Ville Mont-Royal
Québec H4T 1E2
SUBMISSION CONTROL #: 194899
_Priva-CANDESARTAN _
_ _
_ _
_ _
_ _
_ _
_ _
_ _
_ _
_ _
_Page 2 of 35 _
_ _
TABLE OF CONTENTS
CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
...............................................................................
3
SUMMARY PRODUCT INFORMATION
...............................................................................................
3
INDICATIONS AND CLINICAL USE
.....................................................................................................
3
CONTRAINDICATIONS
..........................................................................................................................
4
WARNINGS AND PRECAUTIONS
.........................................................................................................
4
ADVERSE REACTIONS
...........................................................................................................................
8
DRUG INTERACTIONS
.........................................................................................................................
13
DOSAGE AND ADMINISTRATION
.....................................................................................................
16
OVERDOSAGE
.......................................................................................................................................
19
ACTION AND CLINICAL
PHARMACOLOGY....................................................................................
19
STORAGE AND STABILITY
.................................................................................................................
21
DOSAGE FORMS, COMPOSITION AND PACKAGING
................................................................